| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan; and the 2Department of Pharmacology, Kyoto University, Faculty of Medicine, Kyoto, Japan.
PURPOSE. This study was designed to clarify the involvement of the prostanoid FP receptor in the intraocular pressure (IOP)-lowering effects of latanoprost, travoprost, bimatoprost, and unoprostone with the use of FP-receptor–deficient (FPKO) mice.
METHODS. FPKO and wild-type (WT) mice were bred and acclimatized under a 12-hour light–dark cycle. IOP was measured under general anesthesia by a microneedle method. To evaluate the effects of each drug, a single drop (3 µL) of each drug solution was topically applied in a masked manner to a randomly selected eye. IOP reduction was evaluated by the difference in IOP between the treated eye and the untreated contralateral eye in the same mouse. First, the diurnal variation and baseline IOP in WT and FPKO mice were measured. Then, to determine the window feasible for demonstrating the most marked ocular hypotensive effect, 0.005% latanoprost was applied to WT mice during the day or at night. The time when the ocular hypotensive effect was larger was selected for further studies to evaluate the effects of latanoprost (0.005%), travoprost (0.004%), bimatoprost (0.03%), and unoprostone (0.12%). In addition, bunazosin (0.1%) was also applied to demonstrate functional uveoscleral outflow in FPKO mice. All experiments were conducted under a masked study design.
RESULTS. The baseline IOP (mean ± SEM) in WT and FPKO mice was 15.0 ± 0.2 and 15.0 ± 0.3 mm Hg, respectively, during the day, and 18.9 ± 0.4 and 19.2 ± 0.4 mm Hg, respectively, at night. In WT mice, latanoprost significantly lowered IOP both during the day and at night, at 2 to 6 hours and 1 to 6 hours after application, respectively. Maximal IOP reduction was observed at 3 hours after drug instillation both during the day (10.9 ± 1.8%) and at night (23.2 ± 1.1%). At 3 hours after instillation, latanoprost (10.9 ± 1.8% and 23.2 ± 1.1%, daytime and nighttime, respectively), travoprost (15.9 ± 1.4% and 26.1 ± 1.2%) and bimatoprost (8.8 ± 2.0 and 19.8 ± 1.5%) significantly lowered IOP in WT mice both during the day and at night; isopropyl unoprostone significantly lowered IOP at night (13.7 ± 1.9%) but not during the day (5.3 ± 3.2%). In FPKO mice, latanoprost, travoprost, bimatoprost, and unoprostone showed no significant IOP-lowering effect. Bunazosin significantly lowered IOP in both WT (22.1 ± 1.6%) and FPKO mice (22.2 ± 2.1%).
CONCLUSIONS. A single application of latanoprost, travoprost, bimatoprost, or unoprostone had no effect on IOP in FPKO mice with presumed functional uveoscleral outflow pathways. The prostanoid FP receptor plays a crucial role in the mechanism of early IOP lowering of all commercially available prostaglandin analogues.
This article has been cited by other articles:
|
|
 |
|
  T. Saeki, T. Ota, M. Aihara, and M. Araie Effects of Prostanoid EP Agonists on Mouse Intraocular Pressure Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2201 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C B Camras, N A Sharif, M B Wax, and J Stjernschantz Bimatoprost, the prodrug of a prostaglandin analogue Br. J. Ophthalmol., June 1, 2008; 92(6): 862 - 863. [Full Text] [PDF]
|
|
|
|
|
|
L B Cantor Author's reply Br. J. Ophthalmol., June 1, 2008; 92(6): 863 - 864. [Full Text] [PDF]
|
|
|
|
|
|
R.-F. Wang, D. J. Gagliuso, T. W. Mittag, and S. M. Podos Effect of 15-Keto Latanoprost on Intraocular Pressure and Aqueous Humor Dynamics in Monkey Eyes Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4143 - 4147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Crowston, C. A. Morris, J. D. Lindsey, and R. N. Weinreb Prostaglandin FP Receptors Do Not Contribute to 24-hour Intraocular Pressure Variation in Mice Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2095 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ota, M. Aihara, T. Saeki, S. Narumiya, and M. Araie The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice Br. J. Ophthalmol., May 1, 2007; 91(5): 673 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ota, M. Aihara, T. Saeki, S. Narumiya, and M. Araie The Effects of Prostaglandin Analogues on Prostanoid EP1, EP2, and EP3 Receptor-Deficient Mice. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3395 - 3399. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
